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Abstract
Many immune diseases occur at different rates among people with schizophrenia compared to the general population. Here,
we evaluated whether this phenomenon might be explained by shared genetic risk factors. We used data from large
genome-wide association studies to compare the genetic architecture of schizophrenia to 19 immune diseases. First, we
evaluated the association with schizophrenia of 581 variants previously reported to be associated with immune diseases at
genome-wide significance. We identified five variants with potentially pleiotropic effects. While colocalization analyses
were inconclusive, functional characterization of these variants provided the strongest evidence for a model in which
genetic variation at rs1734907 modulates risk of schizophrenia and Crohn’s disease via altered methylation and expression
of EPHB4—a gene whose protein product guides the migration of neuronal axons in the brain and the migration of
lymphocytes towards infected cells in the immune system. Next, we investigated genome-wide sharing of common variants
between schizophrenia and immune diseases using cross-trait LD score regression. Of the 11 immune diseases with
available genome-wide summary statistics, we observed genetic correlation between six immune diseases and
schizophrenia: inflammatory bowel disease (rg = 0.12± 0.03, P=2.49 × 10−4), Crohn’s disease (rg = 0.097±0.06, P=3.27 ×
10−3), ulcerative colitis (rg = 0.11±0.04, P=4.05 × 10–3), primary biliary cirrhosis (rg = 0.13±0.05, P=3.98 × 10−3), psoriasis
(rg = 0.18±0.07, P=7.78 × 10–3) and systemic lupus erythematosus (rg = 0.13±0.05, P=3.76 × 10–3). With the exception of
ulcerative colitis, the degree and direction of these genetic correlations were consistent with the expected phenotypic
correlation based on epidemiological data. Our findings suggest shared genetic risk factors contribute to the
epidemiological association of certain immune diseases and schizophrenia.
Introduction
Despitex recent advances in identifying key biomarkers and ge-
netic loci for schizophrenia, its pathophysiology remains poorly
understood (1,2). One interesting epidemiological observation
is that the risk of developing many immune-mediated diseases
is increased among patients with schizophrenia (3–5) and vice
versa (6,7). Here, we use the term immune disease to broadly
encompass both autoimmune and inflammatory disorders.
While there are discrepancies among studies regarding which
immune diseases are most strongly correlated with schizophre-
nia, there is converging evidence that these diseases co-occur
at a greater rate than is expected by chance (3–7). A notable
exception is rheumatoid arthritis (RA), where a consistent
inverse association with schizophrenia has been observed (5,8).
Genetic factors have long been proposed as an explana-
tion for the differing prevalence of immune diseases among
patients with schizophrenia compared to the general popula-
tion (5,6). The recently reported role of complement component 4
(C4) variation in schizophrenia (9) illustrates a potential shared
genetic mechanism in the development of immune and psychi-
atric disorders. Genetic variants conferring increased C4 expres-
sion protect against developing systemic lupus erythematosus
(SLE), possibly by increased tagging of apoptotic cells—which
are the trigger for autoantibody development in SLE—leading to
more effective clearance by macrophages (10). The same genetic
mechanism may increase the risk of developing schizophre-
nia, by increased tagging of neuronal synapses for elimina-
tion by microglia leading to excessive synaptic pruning (9). We
hypothesize that similar shared genetic mechanisms may occur
throughout the genome,with cellularmanifestations in immune
cells and neurons influencing the development of immune and
psychiatric disorders, respectively. Previously,we found that sus-
ceptibility to schizophrenia does not appear to be driven by the
broad set of loci harboring immune genes (11). However, not all
genetic variants conferring risk of immune disease fall within
immune loci. Here, we evaluated whether common genetic vari-
ants influencing the risk of 19 different immune diseases may
also be involved in schizophrenia.
Our cross-disorder genetic approach is supported by recent
successes in identifying shared genetic risk variants (pleiotropy)
across a variety of human diseases (12–18). The biological inter-
pretation of pleiotropy is challenging, given the various molec-
ular mechanisms that can drive shared genetic risk variants
across complex traits. For instance, pleiotropy can result from
a single-nucleotide polymorphism (SNP) independently influ-
encing two unrelated traits (horizontal pleiotropy), a SNP influ-
encing one trait that is related to or a risk factor for additional
traits (vertical pleiotropy), or a SNP influencing one trait that has
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a high rate of misclassification with or represents a subgroup
of a second trait (clinical heterogeneity) (19,20). Here, we use
the term pleiotropy to refer broadly to a single genetic variant
affecting multiple traits, regardless of the underlying molecular
basis and biological implications. Pleiotropy in this broad sense
is emerging as a pervasive phenomenon in the human genome
(21–23), and cross-disorder studies characterizing the nature of
genotype–phenotype relationships have the potential to yield
significant insights into disease etiology. For instance, cross-trait
genetic analyses have shed new light on cardiovascular disease
and lipid biology, shifting attention away from high-density
lipoprotein cholesterol (HDL) as a potential treatment target
by demonstrating that genetically increased HDL levels do not
reduce the risk of myocardial infarction (14). In psychiatry, cross-
disorder analyses have identified pleiotropic variants between
schizophrenia, bipolar disorder and major depressive disorder,
indicating that these diseases are not as distinct at a pathophys-
iological level as current diagnostic criteria suggest (12,13,24).
While previous studies have investigated genome-wide
pleiotropy between schizophrenia and immune disorders,
results have been inconsistent (Supplementary Data, Table S1).
Genetic correlation has been reported between schizophrenia
and Crohn’s disease [CRO, (25–29)], multiple sclerosis [MS,
(30)], primary biliary cirrhosis [PBC, (27)], psoriasis [PSO,
(27,31)], RA (25,26), SLE (26,27), type 1 diabetes [T1D, (25)] and
ulcerative colitis [UC, (26–29)] in some studies, but not in
others (8,13,16,26,32). Interestingly, negative genetic correlation
(whereby genetic risk protects against developing schizophrenia)
has also been reported for RA (33), in keeping with the inverse
epidemiological association (5,8). Potential explanations for
these inconsistent results across studies include differences in
statistical power due to diverse methodologies and sample sizes
(Supplementary Data, Table S1) and varying degrees of influence
by confounding variables such as population stratification and
linkage disequilibrium (LD). Furthermore, although immune
diseases have a significant sex bias with women at greater risk
overall (34), potential sex-specific effects have not been explored
in cross-trait analyses to date. If sex-specific effects are present,
differences in the proportion of male:female samples across
genome-wide association studies (GWAS) may also contribute
to some of the differences across studies.
Additional studies are needed to reconcile the inconsis-
tencies in existing cross-trait analyses of schizophrenia and
immune disorders, with careful attention towards potential
confounding variables (e.g. population stratification, LD, non-
independence of GWAS samples and sex-specific effects). To
this end, we have performed a comprehensive cross-disorder
analysis of schizophrenia and 19 immune diseases, using
data from large genetic studies in European samples. Our
findings add to a growing body of literature supporting pervasive
pleiotropy between schizophrenia and immune diseases. We
extend existing literature by including 10 immune diseases
that have not previously been compared with schizophrenia,
prioritizing pleiotropic genes through integrative analyses of
multi-omics data and estimating how much of the phenotypic
correlation between schizophrenia and immune diseases was
explained by the genetic correlations we observed.
Results
Defining immune risk variants
We identified immune-mediated diseases with robust GWAS
findings using ImmunoBase (http://www.immunobase.org;
accessed 7 June 2015), an online resource providing curated
GWAS data for immune-related human diseases. These included
the following 19 diseases: alopecia areata (AA), ankylosing
spondylitis (AS), autoimmune thyroid disease (ATD), celiac
disease (CEL), CRO, inflammatory bowel disease (IBD), juvenile
idiopathic arthritis (JIA), MS, narcolepsy (NAR), PBC, primary
sclerosing cholangitis (PSC), PSO, RA, Sjögren’s syndrome (SJO),
SLE, systemic sclerosis (SSC), T1D, ulcerative colitis (UC) and
vitiligo (VIT). Notably, the majority of IBD risk variants were
also risk variants for CRO and/or UC. For 11 of these immune
diseases (see Table 1), we also obtained full GWAS summary
statistics allowing us to conduct additional cross-trait linkage
disequilibrium score regression (LDSC) analyses (16).
Given that human leukocyte antigen (HLA) alleles within the
major histocompatibility complex (MHC) region (chromosome 6:
25–34 Mb) account for a significant proportion of heritability of
immune and inflammatory disorders (35), we considered HLA
and non-HLA risk variants separately in our analyses.Within the
MHC region, we considered only the most strongly associated
HLA variant (including SNPs, imputed HLA amino acid sites and
classical alleles) for each disease based on univariate analysis in
previously published studies (see Table 2), because multivariate
conditional analyses reporting adjusted effect sizes of indepen-
dent HLA variants were not available for all immune diseases.
Outside of the MHC region, we considered all non-HLA variants
curated in ImmunoBase for each of the 19 immune diseases.
The number of genome-wide significant non-HLA risk loci
for each of the 19 immune diseases varied from three (NAR)
to 144 (IBD). Several variants were associated with more than
one immune disease. In total, we identified 581 unique variants
(563 non-HLA variants and 18 HLA variants) associated with
any immune disease at genome-wide significance. We refer to
these variants as immune risk variants. For the complete list
of non-HLA immune risk variants, see Supplementary Data,
Table S2.
Identifying pleiotropic variants implicated in both
immune disease and schizophrenia
First, we evaluated whether there was any evidence of overall
risk allele sharing between each of the 19 immune diseases
and schizophrenia using a binomial sign test. To do this, we
used previously published findings from a GWAS conducted by
the Schizophrenia Working Group of the Psychiatric Genomics
Consortium (1,11). This GWAS represented a meta-analysis of 52
cohorts, comprising a total of 35 476 cases and 46839 controls
and the full data set is referred to here as the PGC2 study.
Overall, the direction of effect for the sets of non-HLA SNPs
associated with each of the 19 immune diseases at genome-
wide significance was not shared with schizophrenia more than
expected by chance (all binomial sign test P>0.05; Supplemen-
tary Data, Fig. S1). Thus, we did not observe evidence of risk
allele sharing between any immune disease and schizophrenia
when using a stringent genome-wide significance threshold to
define immune risk variants. We also evaluated the collective
association of 261 LD-independent, non-HLA immune risk
variants associatedwith at least one of the 19 immune-mediated
diseases, for which LD score and minor allele frequency (MAF)
information were available in the European LD score database
(16). We found significant deviation from the theoretical null
in schizophrenia for immune risk SNPs (λ=1.46). However,
when we compared the association of immune risk SNPs to
that of similar randomly selected SNP sets (Supplementary
Material), we observed no evidence of enrichment (P=0.66;
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Table 1. Description of data sets analyzed
Abr Genome-wide
significant SNPsa
Available GWAS
summary statisticsb
Cases Controls Number of SNPs with
available summary statistics
Schizophrenia SCZ − (1) 35 476 46 839 9444230
Bipolar disorder (+) BP − (12) 6990 4820 1233534
Height (−) HGT − (36) 253 288 − 2085602
Alopecia areata AA 11 − − − −
Ankylosing spondylitis AS 23 − − − −
Autoimmune thyroid disease ATD 7 − − − −
Celiac disease CEL 38 (37) 4533 10 750 523398
Crohn’s disease CRO 119 (38) 5956 14 927 12276506
Inflammatory bowel disease IBD 145 (38) 12 882 21 770 12716150
Juvenile idiopathic arthritis JIA 22 − − − −
Multiple sclerosis MS 103 − − − −
Narcolepsy NAR 3 − − − −
Primary biliary cirrhosis PBC 19 (39) 2764 10 475 1038537
Primary sclerosing cholangitis PSC 12 − − − −
Psoriasis PSO 34 (40) 2178 5175 7586779
Rheumatoid arthritis RA 77 (41) 5539 20 169 2090825
Sjögren’s syndrome SJO 6 − − − −
Systemic lupus erythematosus SLE 19 (42) 4036 6959 7915251
Systemic sclerosis SSC 4 (43) 1486c 3 477c 253 179
Type 1 diabetes T1D 56 (44) 9934 16 956 1943760
Ulcerative colitis UC 96 (38) 6968 20 464 12255263
Vitiligo VIT 16 (45) 1381 14 518 8790155
aWe obtained lists of genome-wide significant SNPs for each immune disease from ImmunoBase and processed them as described in Supplementary Data.
bBecause genome-wide summary statistics were required for the LDSC analysis, we were unable to estimate genetic correlation with schizophrenia for eight immune
diseases for which these data were not available (AA, AS, ATD, JIA, MS, NAR, PSC, SJO); −, negative control; +, positive control.
cOnly the US cohort from this study was available for analysis; Abr, abbreviation; −, not analyzed.
Table 2. Association of top HLA variants for immune diseases in schizophrenia
Immune Disease Schizophrenia
Disease HLA variant P OR P OR r2 with top SCZ SNPa
AA (46) HLA-DRB1#37Asn 4.99×10−73 0.42 4.85×10−9 0.91 0.04
AS (47) HLA-B∗27 <1×10−100 46 0.13 1.05 0
ATD (48) rs2281388 (tags
HLA-DPB1∗05:01)
1.50×10−65 1.64 0.39 1.04b 0
CEL (49) HLA-DQB1#74Ala n.r. 2.14 2.16×10−12 0.89 0.11
CRO (50) HLA-DRB1∗01:03 3.00×10−62 2.51 0.61 0.96 0
IBD (50) HLA-DRB1∗01:03 1.93×10−112 3.01 0.61 0.96 0
JIA (51) rs7775055 3.14×10−174 6.01 0.12 0.94 0
MS (52) HLA-DRB1∗15:01 1.40×10−234 2.92 5.10×10−3 1.06 0
NAR (53) HLA-DQB1∗06:02 1.04×10−120 251 7.30×10−3 1.06 0
PBC (54) HLA-DQA1∗04:01 5.90×10−45 3.06 0.20 0.95 0
PSC (55) HLA-B∗08:01 3.70×10−246 2.82 5.65×10−16 0.84 0.2
PSO (56) HLA-C∗06:02 2.10×10−201 3.26 0.55 0.99 0
RA (57) HLA-DRB1#11Val <1×10−581 3.80 2.68×10−4 1.07 0
SJO (58) HLA-DQB1∗02:01 1.38×10 −95 3.36 3.84×10 −15 0.85 0.11
SLE (59) HLA-DRB1#13Arg 7.99×10−10 1.55c 5.81×10−4 1.07 0
SSC (60) rs17500468 (TAP2) 5.87×10−62 2.87 6.76×10−4 1.07 0
T1D (61) HLA-DQB1#57Ala <1×10−1000 5.17 7.80×10−4 0.95 0.06
UC (50) rs6927022 8.00×10−154 1.49 3.37×10−4 1.06 0.03
VIT (45) rs9271597 (4.7kb
upstream of HLA-DQA1)
3.15×10−89 1.77 0.01 1.04 0
ar2 with rs1233578, the top HLA variant in schizophrenia, was obtained from the GAIN schizophrenia cohort (mgs2).
bEffect size estimate is for HLA-DPB1∗05:01.
cEffect size estimate obtained from Asian sample. n.r., not reported; disease abbreviations as defined in Table 1. Bold font indicates statistically significant association
with schizophrenia.
Supplementary Data, Fig. S2), indicating that immune risk SNPs
were not associated with schizophrenia more than expected by
chance given the polygenic nature of schizophrenia.
Next, we identified potential pleiotropic variants by evalu-
ating the association of individual immune risk variants with
schizophrenia.We considered SNPs associated with schizophre-
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nia at P<8.6×10−5 (Bonferroni correction for 581 tests, 563 non-
HLA and 18 HLA variants) to have pleiotropic effects. Given the
size of the schizophrenia GWAS,wehad over 80%power to detect
pleiotropic SNPs assuming an OR≥1.12 in schizophrenia.
Within the MHC region, we observed four HLA risk alleles
associated with both immune disease and schizophrenia, par-
ticularly in the class II HLA region (Table 2; Supplementary Data,
Fig. S3). These HLA risk alleles were the strongest MHC region
associations for AA (HLA-DRB1 #37 Asn), CEL (HLA-DQB1 #74
Ala), PSC (HLA-B∗08:01) and SJO (HLA-DQB1∗02:01). The presence
of HLA-DRB1 #37 Asn conferred a protective association in both
AA and schizophrenia, but the remaining HLA variants showed
the opposite direction of effect in schizophrenia compared to
immune disease (Table 2; Supplementary Data, Fig. S3). Notably,
none of these four HLA variants were significantly associated
with schizophrenia in previous conditional analyses (9,11), sug-
gesting that their association with schizophrenia may be driven
by LD with other causal variants in the region rather than true
pleiotropy. Thus, we did not focus additional analyses on these
variants.
Outside of theMHC region, five immune risk variants showed
potential pleiotropic effects, with the risk allele for immune
disease also conferring risk for schizophrenia (for regional asso-
ciation plots in schizophrenia and the immune diseases of inter-
est, see Supplementary Data, Fig. S4). These variants have been
previously implicated in CRO (rs6738825, rs13126505, rs1734907),
MS (rs7132277) and CEL (rs296547). To evaluate the pleiotropic
potential of these non-HLA variants, we performed Bayesian
colocalization analysis (62) to estimate the posterior probability
(PP) that the corresponding regional associations were driven by
the same SNP in both schizophrenia and the immune disease
of interest. We used available summary statistics from the PGC2
GWAS and the GWAS reporting these immune risk variants as
genome-wide significant in CRO (63,64), MS (65) and CEL (37).
Notably, the immune disease GWAS summary statistics were not
imputed [total number of SNPs: 953 241 (63), 25 075 (64), 155 756
(65) and 523398 (37)]. Low density SNP coverage across the
genome results in a loss of statistical power to detect colocaliza-
tion, as the true causal variants are unlikely to be genotyped (62).
We observed statistically significant colocalization (PP>0.50) in
the regions of association on chromosomes 2, 4 and 12. Only the
region on chromosome 2 colocalized to the immune SNP of inter-
est, rs6738825 (PP=0.23, Table 3); this region also colocalized to
rs7587251 (PP=0.25), a SNP in high LDwith rs6738825 [r2 = 0.98 in
1000 Genomes Phase 3 CEU Population (66)]. We did not observe
statistically significant colocalization in the region of association
on chromosome 1 (PP=0.06) or chromosome 7 (PP=0.05, Table 3).
Given that our colocalization analyses were susceptible to type
II error for the reasons discussed above, we cannot exclude the
possibility of a shared variant underlying the associations seen
in schizophrenia and immune diseases for these regions.
Next, we used conditional and joint analysis (COJO) (67)
to perform association analyses in the PGC2 schizophrenia
GWAS conditioning on each of the five immune risk variants
(Supplementary Data, Fig. S5). If the immune risk variants
(or SNPs in high LD with them) accounted for the regional
associations seen in schizophrenia, no significant associations
should remain after conditioning on these variants (statistically,
all P>8.6×10−5). We observed no remaining associations with
schizophrenia after conditioning on rs296547 (top SNP after
conditioning: rs111530734, P=1.19×10−3), rs1734907 (top SNP
after conditioning: rs11768688, P=9.79×10−4) and rs13126505
(top SNP after conditioning: rs112786981, P=4.58×10−4). Signif-
icant associations with schizophrenia remained after condi-
tioning on rs6738825 (top SNP after conditioning: rs111744017,
P=8.03×10−6) and rs7132277 (top SNP after conditioning:
rs74240770, P=1.37×10−8), suggesting there may be additional
independent causal variants contributing to the associations in
these regions for schizophrenia.
In order to prioritize genes underlying the five potentially
pleiotropic SNPs, we performed an integrative analysis of GWAS
summary statistics with methylation quantitative trait loci
(mQTL) and expression quantitative trait loci (eQTL) studies
using Summary-data-based Mendelian Randomization (SMR)
and heterogeneity in dependent instruments (HEIDI) (68,69)
(Materials and Methods). Briefly, we obtained summary-level
mQTL and eQTL SNP data described in Wu et al. (69). The
mQTL data were from 1 980 individuals with DNA methylation
measured in peripheral blood (70,71), and eQTL data were from
2 765 individuals with gene expression levels measured in
peripheral blood (72). Notably, rs296547 was not genotyped in
the eQTL data set, and we used rs404339 as a proxy SNP [r2 = 0.85
in 1000 Genomes Phase 3 CEU Population (66)] in SMR analyses
of gene expression for rs296547.
We observed that rs1734907, a SNP associated with both CRO
and schizophrenia, was an mQTL (β =0.47, P=2.13×10−26) and
eQTL (β =−0.24, P=3.54×10−10) for EPHB4 in peripheral blood
(Supplementary Data, Table S3; Fig. 1). rs1734907 showed con-
sistent pleiotropic associations with schizophrenia and EPHB4
DNAm (βSMR =−0.14, pSMR = 3.58×10−5, pHEIDI = 0.12), schizophre-
nia and EPHB4 expression (βSMR =−0.28, pSMR = 2.63×10−4,
pHEIDI = 0.17) and EPHB4DNAmand EPHB4 expression (βSMR = 1.98,
pSMR = 6.56×10−8, pHEIDI = 0.011). These consistent associations
across molecular phenotypes and schizophrenia at the EPHB4
locus suggest EPHB4may be driving the association of rs1734907
in schizophrenia (Fig. 1). Notably, TRIP6 is also a candidate
functional gene underlying the association of rs1734907
with schizophrenia. We observed pleiotropic association for
rs1734907 with schizophrenia and TRIP6 DNAm with inconsis-
tent direction of effect (βSMR = 0.15, pSMR = 5.00×10−5, pHEIDI = 0.17
for probe cg18683606; βSMR =−0.12, pSMR = 2.32×10−5, pHEIDI = 0.18
for probe cg27396824), a trend for association with schizophre-
nia and TRIP6 expression (βSMR =−0.33, pSMR = 6.38×10−4,
pHEIDI = 0.14), but no significant association with TRIP6 DNAm
and TRIP6 expression. Colocalization analyses were inconclusive
with respect to rs1734907 showing pleiotropic association with
schizophrenia and CRO as described above, while conditional
analyses suggested this variant explained the regional associa-
tion seen on chromosome 7 in schizophrenia (Table 3).
We also observed that rs7132277, a SNP associated with
both MS and schizophrenia (Table 3), was an mQTL (β =0.27,
P=2.87×10−11) and eQTL (β =0.32, P=5.23×10−19) for ABCB9
in peripheral blood (Supplementary Data, Table S3). Further-
more, we observed consistent pleiotropic associations for
rs7132277 with schizophrenia and ABCB9 DNAm (βSMR =−0.24,
pSMR = 1.20×10−4, pHEIDI = 0.55), schizophrenia and ABCB9
expression (βSMR = 0.20, pSMR = 3.10×10−5, pHEIDI = 0.17) and ABCB9
DNAm and ABCB9 expression (βSMR =−0.83, pSMR = 9.81×10−8,
pHEIDI = 0.48). Thus, there was consistent association across
molecular phenotypes and schizophrenia at the ABCB9 locus,
suggesting this genemay be driving the association of rs7132277
in schizophrenia. Although the region of association on
chromosome 12 showed statistically significant evidence of
colocalization in schizophrenia and MS, rs7132277 was not the
pleiotropic variant driving this association (Table 3). Thus, our
analyses highlight ABCB9 as a candidate gene underlying the
association of rs7132277 in schizophrenia, but do not implicate
this SNP as a pleiotropic immune variant.
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Figure 1. Prioritizing genes driving the pleiotropic association of rs1734907 in CRO and schizophrenia.
Associations for SNP and SMR analyses across GWAS, eQTL and mQTL data sets for rs1734907. Top plot gray circles illustrate SNP association (−log10 P-value) with
schizophrenia in the PGC2 GWAS,while pink diamonds and blue circles indicate results of SMR tests (−log10 P-value) for association of gene expression and DNAmwith
schizophrenia, respectively, with solid shading indicating probes passing the HEIDI test. Middle plot illustrates SNP association (−log10 P-value) with gene expression
from peripheral blood eQTL data set. Lower plots illustrate SNP association (−log10 P-value) with gene methylation from peripheral blood mQTL data set.
The other potentially pleiotropic SNPs did not demonstrate
consistent localization to a particular gene across traits and
molecular phenotypes (Table 3; Supplementary Data, Table S3).
Detecting genetic correlations between immune disease
and schizophrenia
Our immune risk variant set captured only those variants asso-
ciated with immune diseases at genome-wide significance in
current GWAS. Given the polygenicity of immune-related dis-
eases, there are 100s to 1000s of additional variants associated
with each disease that have not yet been identified (73). To
evaluate sharing of risk alleles between immune diseases and
schizophrenia using a broader set of variants,we used LDSC (16).
LDSC provides an interpretable and comparable estimation of
genetic sharing between two traits in the form of genetic correla-
tion (rg) values; the method uses genome-wide summary statis-
tics, effectively accounts for linkage-disequilibriumand is robust
to non-independence of GWAS samples (16). We therefore used
LDSC to estimate pairwise genome-wide genetic correlations
between schizophrenia and immune diseases. In addition to
the 11 immune diseases with available genome-wide summary
statistics, we included bipolar disorder as a positive control and
height as a negative control. We used summary statistics from
the 49 European-ancestry cohorts in the PGC2 study (33 640 cases
and 43 456 controls) to ensure comparable LD structure across
samples (1).Notably, LDSC is less sensitive than othermethods of
estimating genetic correlation (e.g. polygenic risk scoring (PRS),
genome-based restricted maximum likelihood (GREML)) and is
not robust when applied to genetic data obtained from specialty
chips (e.g. Immunochip) (16). We considered immune diseases
with rg P<0.05 to show genetic overlap with schizophrenia.
As previously reported (16), our positive control (bipolar dis-
order) showed significant genetic overlap with schizophrenia
(rg = 0.75±0.05,P=8.5×10−60, Fig. 2, Table 4) and our negative con-
trol (height) showed no such overlap (rg =−0.004±0.02, P=0.84,
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Figure 2. Genetic correlation between schizophrenia and other traits.
Genetic correlation between schizophrenia, bipolar disorder, height and 14 immune diseases was estimated using cross-trait LDSC (16). Colour intensity and size of
square are proportional to strength of genetic correlation (red,negative correlation; blue,positive correlation).Asterisks indicate genetic correlations that are statistically
significant at P< 0.05 (∗), P< 0.004 (∗∗) and P < 0.0002 (∗∗∗) thresholds. BP, bipolar disorder; CEL, celiac disease; CRO, Crohn’s disease; HGT, height; IBD, inflammatory
bowel disease; PBC, primary biliary cirrhosis; PSO, psoriasis, RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSC, systemic sclerosis; T1D, type 1 diabetes;
UC, ulcerative colitis; VIT, vitiligo.
Fig. 2, Table 4). With respect to immune diseases, we observed
genetic overlap with schizophrenia for CRO, IBD, PBC, PSO, SLE
and UC (rg = 0.10–0.18, Fig. 2, Table 4). Notably, genetic correla-
tions for PSO and UC did not survive correction for the 11
tests performed (Table 4). Unsurprisingly, the genetic correla-
tions between schizophrenia and immune diseaseswere smaller
in magnitude than those of commonly overlapping immune
diseases (e.g. RA and SLE: rg = 0.55±0.08, P=3.60×10−11).
Given the significant sex bias of immune diseases, with
women at greater risk overall (34), we hypothesized that there
may be sex-dependent genetic overlap between schizophre-
nia and some immune-mediated diseases. We therefore
performed exploratory sex-stratified LDSC, estimating genetic
correlation between immune diseases and schizophrenia
separately in males (33 097 schizophrenia cases and 35190
controls) and females (17 760 schizophrenia cases and 36903
controls) of European ancestry from the PGC2 study and
additional PGC samples.We found consistent genetic correlation
estimates across male and female subsamples compared to
the total sample for 9 of the 11 immune diseases investigated
(Table 4). For SLE, we observed significant genetic correlation
with schizophrenia in the total sample and in the male
sample, but not in the female schizophrenia sample. For SSC,
we observed genetic correlation with schizophrenia only in
the male schizophrenia sample. For both SLE and SSC, there
was a trend for the same direction of effect (positive genetic
correlation) among females that did not reach statistical
significance.
Benchmarking genetic correlations between immune
disease and schizophrenia with epidemiological data
To determine how much of the phenotypic correlation between
schizophrenia and immune diseases was explained by the
genetic correlations we observed, we benchmarked significant
genetic correlations between schizophrenia and immune-
mediated disorders relative to the expected phenotypic cor-
relations from epidemiological data (Materials and Methods).
Using incidence of immune diseases in schizophrenia reported
in a large population-based study (3), we estimated phenotypic
correlations between schizophrenia and immune diseases
with available incidence rate ratios in schizophrenia. For
CRO, PBC, PSO and SLE, we observed small positive genetic
correlations with schizophrenia that were consistent with the
epidemiological data (Table 4). For UC, we observed a small
positive estimate of genetic correlation (rg = 0.106 ± 0.04) while
there was no strong evidence for any correlation between UC
and schizophrenia in the epidemiological data (rp =−0.001).
Importantly, while the MHC region contains risk factors for both
schizophrenia and immune diseases, our genetic correlation
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Table 4. Estimated phenotypic and genome-wide genetic correlations between schizophrenia and other traits, r2 and h2 are reported on the
observed scale for all diseases.
Total sample Male-specific Female-specific
Trait h2 ± SEa rp rg ± SE P rg ± SE P rg ± SE P
BP (+) 0.46 ± 0.02 0.75 ± 0.05 4.02×10−57 0.657 ± 0.04 3.23×10−52 0.820 ± 0.06 1.69×10−49
HGT (−) 0.34 ± 0.02 7.47×10−5 ± 0.02 0.99 −0.012 ± 0.02 0.53 0.012 ± 0.02 0.60
CEL 0.23 ± 0.05 0.04 0.107 ± 0.06 0.05 0.055 ± 0.06 0.34 0.075 ± 0.07 0.29
CRO 0.37 ± 0.04 0.04 0.097 ± 0.03 3.27×10−3 0.103 ± 0.03 9.17×10−4 0.110 ± 0.04 8.85×10−3
IBD 0.32 ± 0.04 n.a. 0.117 ± 0.03 2.49×10−4 0.114 ± 0.03 1.14×10−4 0.139 ± 0.04 6.09×10−4
PBC 0.46 ± 0.08 0.11 0.131 ± 0.05 4.00×10−3 0.141 ± 0.04 1.50×10−3 0.073 ± 0.05 0.15
PSO 0.27 ± 0.09 0.13 0.182 ± 0.07 7.80×10−3 0.205 ± 0.07 4.10×10−3 0.212 ± 0.09 0.01
RA 0.18 ± 0.03 −0.04 −0.032 ± 0.04 0.78 0.017 ± 0.04 0.70 −0.067 ± 0.05 0.19
SLE 0.13 ± 0.05 0.05 0.130 ± 0.05 3.76×10−3 0.153 ± 0.05 1.51×10−3 0.065 ± 0.05 0.22
SSC 0.26 ± 0.08 n.a. 0.086 ± 0.07 0.16 0.190 ± 0.09 0.04 0.011 ± 0.09 0.91
T1D 0.20 ± 0.04 0.15 −0.008 ± 0.05 0.86 0.041 ± 0.05 0.38 −0.013 ± 0.05 0.81
UC 0.23 ± 0.03 −0.001 0.106 ± 0.04 4.00×10−3 0.121 ± 0.04 9.87×10−4 0.153 ± 0.05 8.98×10−4
VIT 0.86 ± 0.15 n.a. 0.011 ± 0.05 0.84 0.060 ± 0.05 0.23 0.045 ± 0.07 0.51
ah2 was estimated using LDSC.
(+), positive control; (−), negative control; n.a., not available due to lack of data regarding incidence rate ratio of this immune disease in schizophrenia; SE, standard
error; rg, genetic correlation; rp, expected phenotypic correlation based on epidemiological data (see Materials and Methods for details of rp estimation). Bold font
indicates significant genetic correlation with schizophrenia (P < 0.05)
r2 and h2 are reported on the observed scale for all diseases.
estimates were obtained considering only SNPs outside of the
MHC due to unusual LD in this region (74).
Discussion
Using a variety of statistical approaches, we provide evidence
of shared genetic risk for schizophrenia and immune diseases.
Within the MHC region,we identified four HLA variants showing
statistically significant association with schizophrenia. An
important caveat is that these four variants were not the
top variants in their respective regions of association with
schizophrenia and were not primary drivers of the MHC
association in schizophrenia in stepwise conditional analyses
(9,11). Therefore, the biological significance of these particular
HLA variants in schizophrenia is likely limited.
Outside of the MHC region, we identified five SNPs with
potential pleiotropic effects—influencing risk for both schizophre-
nia and CEL (rs296547), CRO (rs1734907, rs13126505, rs6738825)
or MS (rs7132277). These variants do not appear to be broadly
pleiotropic across human traits, as there were no phenome-wide
significant results reported for any of these SNPs in the PheWAS
catalog (all P>1.2×10−8; all false discovery rate (FDR)>0.1 (75)).
Integration of GWAS,mQTL and eQTL data implicatedABCB9 and
EPHB4/TRIP6 as functional candidates underlying the association
of rs7132277 and rs1734907, respectively. Although ABCB9
emerged as a functional candidate driving the association of
rs7132277 in schizophrenia, the significant colocalization of this
region between schizophrenia and MS (PP=0.94) was not driven
by rs7132277 (PP=1.38×10−39). Overall, our findings provide the
strongest evidence for rs1734907 as a functional, pleiotropic
immune variant associated with both CRO and schizophrenia. In
particular, our results suggest amodel inwhich genetic variation
at rs1734907 (∼85 kb upstream of EPHB4) increases DNA methy-
lation, upregulates EPHB4 expression and decreases the risk of
schizophrenia. While DNA methylation is classically associated
with gene silencing, the effect of methylation on transcription
depends on the genomic context (76); for instance, methylation
of silencers or insulators eliminates transcription-blocking
activity thereby promoting gene expression (77,78). EPHB4 is
a transmembrane tyrosine kinase receptor that coordinates cell
movement via bidirectional intercellular signaling at sites of
direct cell-to-cell contact (79). In the brain, ephrin signaling
mediates synaptic plasticity by initiating and stabilizing
neuronal synapse formation (reviewed in 80). An analogous role
has not yet been discovered in the immune system, possibly
due to the much shorter lifespan of immunological synapses
between lymphocytes and antigen presenting cells (minutes)
as compared to neuronal synapses (years) (81,82). Interestingly,
ephrin signaling attenuates the migration responses of both
neurons and immune cells toward chemoattractants in vitro
(83,84). Thus, pathfinding may be a shared risk mechanism by
which EPHB4 contributes to immune disease and schizophrenia.
The hypotheses raised by our findings require further validation.
If the association of rs1734907 with CRO and schizophrenia is
robustly replicated in future GWAS, functional studies will be
needed to investigate both the genetic mechanism by which
rs1734907 (or a causal variant in LD with this SNP) influences
EPHB4 transcription and the biological mechanism by which
increased EPHB4 expression influences susceptibility to CRO and
schizophrenia.With themulti-kinase inhibitor dasatinib already
on the market for treatment of chronic myeloid leukemia (85)
and other EphB4 inhibitors currently in phase II trials (86–89), the
potential for future drug repurposing makes EPHB4 an attractive
candidate for further investigation.
We observed genome-wide sharing of risk variants for
schizophrenia and six immune diseases (IBD including both
CRO and UC, PBC, PSO, SLE) using LDSC, all of which have
been previously reported to co-occur with schizophrenia in
epidemiological studies (3,5).With the exception of UC, the small
positive genetic correlations observed between these immune
diseases and schizophrenia (rg∼0.1) were consistent with
phenotypic correlations observed in epidemiological data. Thus,
currently available genetic data suggest that shared genetic risk
contributes to the co-occurrence of CRO, PBC, PSO and SLE in
schizophrenia. We note that most of the phenotypic correlation
between these immune diseases and schizophrenia appears
to be captured by common genetic variation. Interestingly,
phenotypic correlations for the remaining five immune diseases
were similar in magnitude (rp = 0.04–0.15), but no genetic
correlation was detected. Possible explanations for this include
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inadequate statistical power to detect genetic correlations
for these diseases in our study or a stronger environmental
component contributing to the epidemiological relationship
of these disorders with schizophrenia. Some of the immune
diseases that did show significant genetic correlation with
schizophrenia (CRO, UC) are considered autoinflammatory
diseases (90), and the others (PBC, PSO, SLE) have a strong
inflammatory component (90–92). This raises the possibility
that the genetic risk we observed between these particular
immune diseases and schizophrenia reflects a subgroup of
inflammation-driven schizophrenia cases and/or sharing of
specific innate immunity pathways between schizophrenia and
these particular immune diseases.
To our knowledge, this is the first time that sex-dependent
genetic correlation with immune diseases has been investigated
in schizophrenia. Interestingly, SLE and SSC showed significant
genetic correlation with schizophrenia only among males in
sex-stratified analyses. Our findings raise the possibility of
male-specific pleiotropy between schizophrenia and certain
immune diseases. Interestingly, animal studies indicate that sex
hormones have opposing effects on predisposition to schizophre-
nia and autoimmunity; estrogen has been reported to protect
against the development of schizophrenia (93), while androgens
appear to protect against the development autoimmune
diseases (94,95). We emphasize that our sex-dependent findings
require validation in independent samples.
Ourworkwas subject to several important limitations. Firstly,
we did not have access to imputed data sets for the origi-
nal immune disease GWAS reporting the potentially pleiotropic
SNPs (Table 3). Lack of dense SNP coverage in the regions of
interest resulted in low power to detect colocalizing associa-
tion in schizophrenia, and thus our analyses are inconclusive
with respect to pleiotropic potential for the two regions that
did not show significant colocalization. Secondly, genome-wide
summary statistics were not available for all of the immune
diseases, resulting in a more limited analysis of 11 diseases
for estimating genetic correlations. Thirdly, we used LDSC to
estimate genetic correlations because of its robustness to non-
independence of GWAS samples as many of the samples ana-
lyzed included Wellcome Trust Case Control Consortium sam-
ples. Compared to alternative methods for estimating genetic
correlation that use individual-level genotype data, LDSC has
lower statistical power. Thus, we cannot exclude the possibility
of additional immune-schizophrenia genetic relationships not
identified in our analyses. Finally, we had greater statistical
power to detect genetic correlation with immune diseases in
the male-specific schizophrenia GWAS compared to the female-
specific GWAS. This difference in power may account for the
male-specific genetic correlations we observed for SLE and SSC,
as opposed to sex-dependent pleiotropic effects.
Despite these limitations, our work adds to a growing
body of evidence suggesting that schizophrenia and immune
diseases share genetic risk factors. There are conflicting
reports in the literature with respect to the specific immune
diseases demonstrating genetic overlap with schizophrenia
and the direction of effect (positive or negative genetic
correlation). Genetic overlap with schizophrenia has been
previously investigated for 9 of the 19 immune diseases studied
here. Genome-wide genetic correlation with schizophrenia
has been previously reported for CRO (25–29), MS (30), PBC
(27), PSO (27,31), RA [both positive (25,26) and negative (33)
genetic correlations], SLE (26,27), T1D (25) and UC (26–29)
(see Supplementary Data, Table S1 for a summary of previous
studies). Our results are consistent with previously reported
genetic overlap between schizophrenia and CRO (25–29), PBC
(27), PSO (27,31), SLE (26,27) and UC (26–29). We did not find
any significant genetic correlation between schizophrenia
and CEL, T1D, RA, SSC or VIT. For RA in particular, there is a
robust inverse epidemiological association with schizophrenia
(8). However, the genetic association is less consistent. Using
methods based on summary statistics (including PRS and
LDSC), six previous studies reported no evidence of pleiotropy
between schizophrenia and RA (8,16,27–29,32), while two studies
reported positive genetic correlation (25,26). Notably, Lee et al.
(33) reported an inverse genetic correlation—in keeping with
the observed epidemiological effect—using GREML, a method
utilizing full genotype data that has greater statistical power
to detect small pleiotropic effects than PRS or LDSC. Given the
modest genetic correlations observed in the present study, subtle
differences in statistical power across studies using different
statistical methods and GWAS data sets may explain these
discrepant findings. As genetic samples continue to grow, and
our understanding of the degree of genetic overlap expected
among complex traits evolves, it will be worthwhile to revisit
these analyses.
Overall, our analyses provide statistical evidence supporting
extensive pleiotropy between immune diseases and schizophre-
nia. Our results highlight EPHB4, a transmembrane receptor that
coordinates cell migration and has dual roles in immune cell
and neuronal pathfinding, as a promising candidate for future
functional studies.More broadly, our findings indicate that com-
mon genetic variants influencing the risk of immune diseases—
in particular CRO, PBC, PSO, SLE and UC—are also involved in
schizophrenia. Studies identifying the cell types and biological
pathways that may be driving this genetic overlap are needed
and will hopefully provide further insights into the pathophysi-
ology of schizophrenia. In the meantime, our work supports the
emerging hypothesis that pathogenic mechanisms are shared
across immune and central nervous system disorders.
Materials and Methods
Samples and quality control
We used either imputed genotype data or summary statistics
generated as described in the original GWAS. For sample details,
see Table 1.
Schizophrenia data set
We used data from the PGC2 study (1). For analyses of non-HLA
genome-wide significant risk variants for immune diseases,
we used publicly available summary statistics from the total
data set (52 cohorts, 35 476 cases and 46839 controls) (1). For
LDSC analyses, we used all 49 European ancestry case-control
cohorts in PGC2 (33 640 cases and 43 456 controls). For analyses
including HLA variants, we used a further refined 31 European
ancestry case-control cohorts (20 253 cases and 25011 controls)
with high-quality coverage of the MHC region, as previously
described (11).
Immune disease data sets
To estimate the extent of genetic overlap between schizophrenia
and immune diseases, we obtained full GWAS summary statis-
tics for 11 of the 19 immune diseases (eight immune diseases
were not included in LDSC analyses due to lack of available
summary statistics). We obtained publicly available summary
statistics for five immune diseases (see URLs): CRO (38), IBD
3508 Human Molecular Genetics, 2019, Vol. 28, No. 20
(38), RA (41), SLE (42) and UC (38). For the following six immune
diseases, we obtained summary statistics with permission from
the authors: CEL (65), PBC (39), PSO (40), SSC (43), T1D (44) and
VIT (45).
Testing the association of genome-wide significant risk
alleles for 19 immune diseases in schizophrenia
For each of the 19 immune diseases, we defined risk loci outside
of the MHC region (chromosome 6: 25–34 Mb) using curated
GWAS results from ImmunoBase (http://www.immunobase.org;
accessed 7 June 2015. For details, see Supplementary Data).
Notably, the majority of IBD risk variants were also risk variants
for CRO and/or UC. Within the MHC region, we considered
only the most strongly associated HLA variant (including SNPs,
imputed HLA amino acid sites and classical alleles) for each
disease based on univariate analysis in previously published
studies (see Table 2), because multivariate conditional analyses
reporting adjusted effect sizes of independent HLA variants
were not available for all immune diseases. In total, there
were 581 unique variants (563 non-HLA variants and 18 HLA
variants) associated with any immune disease at genome-wide
significance. A complete list of non-HLA and HLA immune
risk variants is provided in Table 2 and Supplementary Data,
Table S2, respectively.
First,we tested for shared direction of effect with schizophre-
nia among SNPs associated with each of the 19 immune dis-
eases using the binomial sign test. Because some immune risk
SNPs were associated with multiple diseases with inconsis-
tent direction of effect, we could not evaluate shared direc-
tion of effect among the collective set of immune risk SNPs in
schizophrenia.
Next, we evaluated the collective association of SNPs associ-
ated with any immune disease. First, we extracted the P-values
from the PGC2 GWAS for a pruned set of 261 LD-independent,
non-HLA immune risk SNPs with LD score and MAF information
available in the European LD score database (16). We then
quantified enrichment of these immune risk SNP associations in
schizophrenia using the genomic inflation value λ. We obtained
an empirical enrichment P-value by comparing this to λ values
from 1000 equal-sized sets of SNPs drawn from the schizophre-
nia GWAS summary data and matched to the immune SNP set
for MAF and LD score, as these parameters are correlated with
GWAS test statistics (see Supplementary Data for details).
Finally, we evaluated the association of each of the 581 vari-
ants with schizophrenia using previously published association
results for non-HLA (1) and HLA variants (11). We considered
SNPs associated with schizophrenia at P<8.6×10−5 (Bonferroni
correction for 581 tests, 563 non-HLA and 18 HLA variants) to
have pleiotropic effects.
To evaluate the pleiotropic potential of immune risk variants
significantly associated with schizophrenia, we tested for
colocalization of association signals in immune diseases and
schizophrenia using the Bayesian coloc2 method implemented
in the R package coloc (63). We used window sizes that
captured all SNPs showing r2 >0.2 with each immune risk
variant (chr1:200.8-201.2Mb, chr2:198.0-199.0Mb, chr4:102.6-
103.4Mb, chr7:100.2-100.5Mb, chr12:123.4-123.9Mb). We used
default prior probabilities for immune risk variants being
associated with immune disease (P =1×10−4), schizophrenia
(P=1×10−4) and both immune disease and schizophrenia
(P=1×10−5) as recommended. In addition to colocalization
testing, we performed COJO using GCTA (96). Specifically,
we used COJO to perform association analyses in the PGC2
schizophrenia GWAS conditioning on the immune risk vari-
ants of interest (i.e. SNPs that were significantly associated
with both an immune disease and schizophrenia). If the
immune risk variants explained the regional associations in
schizophrenia, no significant associations with schizophrenia
should remain after conditioning on these variants (statis-
tically, all P>8.6×10−5). We used the 1000 Genomes Phase 3
European data set as a reference panel to calculate LD between
SNPs.
To prioritize genes and regulatory elements driving the
pleiotropic GWAS loci we identified (associated with both
immune disease and schizophrenia, see Table 3), we followed
the analytic approach described by Wu et al. (69). This approach
integrates summary statistics from independent mQTL studies,
eQTL studies and GWAS to identify SNPs associated with
gene expression, DNA methylation and disease through shared
genetic effects.
We obtained mQTL and eQTL data used in Wu et al. (69) for
genetic regions within a 2 Mb window of each pleiotropic SNP.
These data and the quality control measures applied have been
described in detail elsewhere (70). Briefly, mQTL summary-level
SNP data were from a meta-analysis of the Brisbane Systems
Genetics Study (70) and Lothian Birth Cohorts of 1921 and 1936
(71), which comprised 1 980 individuals with DNA methylation
measured in peripheral blood. eQTL summary-level SNP data
were from the Consortium for the Architecture of Gene Expres-
sion (CAGE) study (72), which comprised 2 765 individuals with
gene expression levels measured in peripheral blood. GWAS
summary-level SNP data for schizophrenia was from the PGC2
study (1).
We applied SMR using GCTA (96) to test for shared associa-
tions between the pleiotropic SNPs with DNAm probes and gene
expression probes, DNAm probes and schizophrenia and gene
expression probes and schizophrenia.We considered significant
associations as those with pSMR <1.30×10−4 (0.05/385 tagged
genes) for mQTLs and pSMR <4.31×10−4 for eQTLs (0.05/116
tagged genes). Next, we applied the HEIDI test (68) using GCTA
(96) to evaluatewhether significant shared associations between
DNAm, gene expression and schizophrenia were driven by
linkage (i.e. separate causal variants in LD exerting genetic
effects on DNAm, gene expression and schizophrenia) or a
shared pleiotropic causal variant. We considered genetic effects
that passed the HEIDI test (pHEIDI >0.01) to be driven by a single
causal variant. We looked for consistent SMR and HEIDI results
across GWAS, mQTL and eQTL studies to prioritize genes for
future functional studies.
Estimating the degree of genetic correlation between
schizophrenia and 14 immune diseases
To evaluate whether common variants influencing risk of
immune diseases collectively contribute to schizophrenia, we
used cross-trait LDSC (16). Cross-trait LDSC estimates the
genetic correlation (rg) between two traits using GWAS summary
statistics. Our main analysis included 11 immune diseases with
available genome-wide summary statistics. To benchmark the
amount of genetic overlap between schizophrenia and immune
disease, we included bipolar disorder as a positive control (12)
and human height as a negative control (36) based on their
previously reported genetic correlations with schizophrenia
using cross-trait LDSC (16).
The statistical framework for cross-trait LDSC has been
described in detail previously (16). Briefly, LDSC leverages
the relationship between LD and association test statistics to
Human Molecular Genetics, 2019, Vol. 28, No. 20 3509
estimate heritability as the slope of the regression of z-scores
against LD scores (97). Cross-trait LDSC is a bivariate extension
of this method that estimates genetic covariance as the slope
of the regression of the products of z-scores against LD scores
using the following equation (16):
E
[‡1j‡2|j] =
√
N1N2g
M
j + NS√
N1N2
where ‡ij denotes the z score for study i and SNPj, j is the LD
score (96), Ni is the sample size for study i, g is the genetic
covariance, M is the number of SNPs in the reference panel
with MAF between 5% and 50%, NS is the number of indi-
viduals included in both studies and  is the phenotypic cor-
relation among the NS overlapping samples. Genetic covari-
ance g is estimated by regressing ‡1j‡2 against j
√
N1N2 and
multiplying the resulting slope by M. Statistical significance is
assessed using block jackknifing over 200 equally sized blocks
of SNPs (16). Importantly, the MHC region is excluded from
LDSC analyses due to its unusual LD structure and genetic
architecture (74).
Because LDSC is robust to sample sharing across GWAS (16),
we used summary statistics from the 49 European-ancestry
cohorts in the PGC2 study (33 640 cases and 43456 controls) (1).
We used LD scores from the ‘eur_w_ld_chr/’ files available from
https://data.broadinstitute.org/alkesgroup/LDSCORE, computed
using 1000 Genomes Project (66) Europeans as a reference panel
as previously described (74). To ensure we were using well-
imputed SNPS, we filtered all GWAS as previously described
(16), including limiting the analysis to HapMap 3 (98) SNPs as
implemented in the LDSC script munge_sumstats.py (https://
github.com/bulik/ldsc). We estimated h2 for each trait on the
observed scale (Supplementary Data, Table S4). We considered
traits with rg P<0.05 to have significant genetic correlation with
schizophrenia.
Benchmarking with epidemiological data
To determine how much of the phenotypic correlation between
schizophrenia and immune-mediated diseases was explained
by the genetic correlations we observed, we used the approach
previously described by Lee et al. (33). Briefly, we benchmarked
our genetic correlation estimates between schizophrenia
and immune diseases relative to the expected phenotypic
correlations from epidemiological data. We obtained estimates
of the population risk of schizophrenia (KSCZ), the population
risk of each immune disease (KIMMUNE) and the probability of each
immune disease among patients with schizophrenia (KIMMUNE|SCZ)
from the literature as referenced in Supplementary Data,
Table S4. We estimated the phenotypic correlation between
schizophrenia and the immune disease of interest (RSCZ-IMMUNE)
using the following formula, as derived by Lee et al. (33) assuming
that the phenotypic liabilities of schizophrenia (lSCZ) and
immune disease (lIMMUNE) follow a bivariate normal distribution
with mean=0 and standard deviation=1:
RSCZ−IMMUNE =
iSCZtIMMUNE−
√
i2SCZt
2
IMMUNE−
(
t2IMMUNE|SCZ+i2SCZ
)(
t2IMMUNE−t2IMMMUNE|SCZ
)
(
t2IMMUNE|SCZ + i2SCZ
)
where:
tSCZ is the liability threshold for schizophrenia: Z-score of the
(1 − KSCZ)th percentile
tIMMUNE is the liability threshold for immune disease: Z-score
of the (1 − KIMMUNE)th percentile
tIMMUNE|SCZ is the liability threshold for immune disease in
those with schizophrenia: Z-score of the (1−KIMMUNE|SCZ)th
percentile
dSCZ is the ‘height’ of the normal distribution at the
schizophrenia liability threshold: probability density
function of tSCZ
iSCZ is the mean phenotypic liability of those with
schizophrenia:
dSCZ/KSCZ
Statistical power
Power to detect association of individual non-HLA and HLA
immune risk variants in schizophrenia was calculated using the
Genetic Power Calculator (99) assuming a risk allele frequency
(RAF) of 0.05, disease prevalence of 1% and significance thresh-
old (α) of 8.6×10−5. We used a RAF of 0.05 as this was the point
at which statistical power remained >80% given the prevalence
of schizophrenia and size of our sample. The vast majority of
immune variants had MAF >0.05 (551/563 variants).
URLs
LD score database: ftp://atguftp.mgh.harvard.edu/brendan/1k_
eur_r2_hm3snps_se_weights.RDS.
Publicly available GWAS summary statistics:
• CRO, IBD,UC ftp://ftp.sanger.ac.uk/pub/consortia/ibdgenet
ics/iibdgc-trans-ancestry-filtered-summary-stats.tgz.
• RA http://www.broadinstitute.org/ftp/pub/rheumatoid_
arthritis/Stahl_etal_2010NG/.
• SLE https://www.immunobase.org/downloads/protected_
data/GWAS_Data/hg19_gwas_sle_bentham_4_20_0.tab.gz.
Supplementary Material
Supplementary Data is available at HMG online.
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